Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS)

NCT06636786 is registered in ClinicalTrials.gov with University of North Carolina, Chapel Hill as lead sponsor.

NCT NCT06636786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06636786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS)
Lead sponsor
University of North Carolina, Chapel Hill
Phase
Phase 2
Overall status
Recruiting
Start date
March 25, 2025
Completion date
September 30, 2026
Enrollment
180 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

acute stress disorder, acute stress reaction, neurocognitive function, post-traumatic stress